China Biologic Products to Report Fourth Quarter and Fiscal Year 2018 Financial Results
BEIJING, Feb. 25, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its fourth quarter and fiscal year 2018 financial results on Wednesday, March 6, 2019 after the market closes.
The Company's management will hold a conference call at 7:30 a.m. ET on Thursday, March 7, 2019, which is 8:30 p.m. Beijing Time on March 7, 2019, to discuss fourth quarter and fiscal year 2018 results. Listeners may access the call by dialing:
1 888 346 8982
1 412 902 4272
A telephone replay will be available one hour after the conclusion of the conference call through March 14, 2019. The dial-in details are:
1 877 344 7529
1 412 317 0088
A live and archived webcast of the conference call will be available through the Company's investor relations website at http://chinabiologic.investorroom.com/.
About China Biologic Products Holdings, Inc.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutical company in China. The Company's products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosage forms of plasma products through its indirect majority-owned subsidiary, Shandong Taibang Biological Products Co., Ltd. and its wholly owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals, distributors and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.
China Biologic Products Holdings, Inc.
Mr. Ming Yin
Senior Vice President
The Foote Group
Mr. Philip Lisio
SOURCE China Biologic Products Holdings, Inc.